LINC00520 and breast carcinoma: Furthermore, LINC00520 increases the expression of POSTN, CCNE2, or HSP27 by targeting miR-577, thereby accelerating the progression of breast cancer, non-small cell lung cancer, or colorectal cancer [41–43].